OBJECTIVES: The aims of this study were to investigate the influence of alendronate and intra-articular betamethasone treatment on bone mineral density (BMD) changes in hand, lumbar spine and femoral neck during 1 year of a treat-to-target study (Cyclosporine, Methotrexate, Steroid in RA (CIMESTRA)). PATIENTS AND METHODS: A hundred and sixty patients with early, active rheumatoid arthritis (RA) receivedmethotrexate, intra-articular betamethasone and ciclosporin /placebo-ciclosporin. Patients with Z-score ≤0 also startedalendronate 10 mg/day. BMD of the hand (digital x-ray radiogrammetry (DXR-BMDhand)), BMD of lumbar spine and femoral neck (dual x-ray absorptiometry (DXA-BMDlumbar spine and DXA-BMDfemoral neck)) and x-rays of hands, wrists and forefeet (modified Sharp-van der Heijde score) were measured at baseline and 1 year, with complete data available in 107 patients. RESULTS: The change in BMD in hand, lumbar spine and femoral neck was negatively associated with the dose of intra-articular betamethasone (p<0.01 for all), but the bone loss in hand was modest and in the axial skeleton comparable with that of healthy individuals. Alendronate did not influence changes in DXR-BMDhand, which averaged -2.8%, whereas significant changes were observed in DXA-BMDlumbar spine and DXA-BMDfemoral neck in alendronate-treated patients (1.8% and 0.8%) compared with untreated patients (-1.8% and -2.2%) (p<0.01 and 0.02). Alendronate did not affect the radiographic progression (alendronate-treated patients: 0 (range 0-19), non-alendronate: 0 (0-18)). CONCLUSIONS: In early active RA, intra-articular betamethasone injections added to disease-modifying antirheumatic drug (DMARD) treatment led to minimal loss of hip and lumbar BMD, and the loss could be prevented by treatment with alendronate. Alendronate treatment did not affect radiographic progression.
RCT Entities:
OBJECTIVES: The aims of this study were to investigate the influence of alendronate and intra-articularbetamethasone treatment on bone mineral density (BMD) changes in hand, lumbar spine and femoral neck during 1 year of a treat-to-target study (Cyclosporine, Methotrexate, Steroid in RA (CIMESTRA)). PATIENTS AND METHODS: A hundred and sixty patients with early, active rheumatoid arthritis (RA) received methotrexate, intra-articularbetamethasone and ciclosporin /placebo-ciclosporin. Patients with Z-score ≤0 also started alendronate 10 mg/day. BMD of the hand (digital x-ray radiogrammetry (DXR-BMDhand)), BMD of lumbar spine and femoral neck (dual x-ray absorptiometry (DXA-BMDlumbar spine and DXA-BMDfemoral neck)) and x-rays of hands, wrists and forefeet (modified Sharp-van der Heijde score) were measured at baseline and 1 year, with complete data available in 107 patients. RESULTS: The change in BMD in hand, lumbar spine and femoral neck was negatively associated with the dose of intra-articularbetamethasone (p<0.01 for all), but the bone loss in hand was modest and in the axial skeleton comparable with that of healthy individuals. Alendronate did not influence changes in DXR-BMDhand, which averaged -2.8%, whereas significant changes were observed in DXA-BMDlumbar spine and DXA-BMDfemoral neck in alendronate-treated patients (1.8% and 0.8%) compared with untreated patients (-1.8% and -2.2%) (p<0.01 and 0.02). Alendronate did not affect the radiographic progression (alendronate-treated patients: 0 (range 0-19), non-alendronate: 0 (0-18)). CONCLUSIONS: In early active RA, intra-articularbetamethasone injections added to disease-modifying antirheumatic drug (DMARD) treatment led to minimal loss of hip and lumbar BMD, and the loss could be prevented by treatment with alendronate. Alendronate treatment did not affect radiographic progression.
Entities:
Keywords:
DXA; DXR; Intra-articular glucocorticoid; alendronate; bone mineral density; early RA; osteoporosis
Authors: L M Ørnbjerg; M Østergaard; T Jensen; K Hørslev-Petersen; K Stengaard-Pedersen; P Junker; T Ellingsen; P Ahlquist; H Lindegaard; A Linauskas; A Schlemmer; M Y Dam; I Hansen; T Lottenburger; C G Ammitzbøll; A Jørgensen; S B Krintel; J Raun; M L Hetland; Ole Slot; Lars Kjær Nielsen; Henrik Skjødt; Ole Majgaard; Tove Lorenzen; Hans Christian Horn; Marcin Kowalski; Inger Lauge Johansen; Peter Mosborg Pedersen; Natalia Manilo; Henning Bliddal Journal: Clin Rheumatol Date: 2016-12-05 Impact factor: 2.980
Authors: T Shimizu; M Takahata; H Kimura-Suda; Y Kameda; K Endo; H Hamano; S Hiratsuka; M Ota; D Sato; T Ito; M Todoh; S Tadano; N Iwasaki Journal: Osteoporos Int Date: 2016-10-04 Impact factor: 4.507
Authors: Serena Bugatti; Laura Bogliolo; Antonio Manzo; Ludovico De Stefano; Paolo Delvino; Francesca Motta; Carlomaurizio Montecucco Journal: Front Immunol Date: 2021-06-14 Impact factor: 7.561